- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2509-4254
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma ; day:24 ; month:1 ; year:2019 ; pages:1-14
PharmacoEconomics - open ; (24.1.2019), 1-14
- Urheber
-
Bullement, Ash
Nathan, Paul
Willis, Anna
Amin, Amerah
Lilley, Cameron
Stapelkamp, Ceilidh
Hatswell, Anthony
Pescott, Chris
Bharmal, Murtuza
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s41669-018-0115-y
- URN
-
urn:nbn:de:101:1-2019030122023431926124
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bullement, Ash
- Nathan, Paul
- Willis, Anna
- Amin, Amerah
- Lilley, Cameron
- Stapelkamp, Ceilidh
- Hatswell, Anthony
- Pescott, Chris
- Bharmal, Murtuza
- SpringerLink (Online service)
Ähnliche Objekte (12)
Metastatic Merkel cell carcinoma response to nivolumab
Metastatic Merkel Cell Carcinoma of the Abdominal Wall
Challenges of New Approaches in Metastatic Merkel Cell Carcinoma
Erratum to: Metastatic Merkel cell carcinoma response to nivolumab
Cost‑effectiveness analysis of tislelizumab plus chemotherapy in Chinese patients with advanced or metastatic oesophageal squamous cell carcinoma
Asymptomatic recurrence detection and cost-effectiveness in urothelial carcinoma
Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
Cost-Effectiveness of Fruquintinib for Refractory Metastatic Colorectal Cancer in the USA
Merkel cell carcinoma
Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma
Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma
Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
Metastatic Merkel cell carcinoma response to nivolumab
Metastatic Merkel Cell Carcinoma of the Abdominal Wall
Challenges of New Approaches in Metastatic Merkel Cell Carcinoma
Erratum to: Metastatic Merkel cell carcinoma response to nivolumab
Cost‑effectiveness analysis of tislelizumab plus chemotherapy in Chinese patients with advanced or metastatic oesophageal squamous cell carcinoma
Asymptomatic recurrence detection and cost-effectiveness in urothelial carcinoma
Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
Cost-Effectiveness of Fruquintinib for Refractory Metastatic Colorectal Cancer in the USA
Merkel cell carcinoma
Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma
Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma
Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
Metastatic Merkel cell carcinoma response to nivolumab
Metastatic Merkel Cell Carcinoma of the Abdominal Wall
Challenges of New Approaches in Metastatic Merkel Cell Carcinoma
Erratum to: Metastatic Merkel cell carcinoma response to nivolumab
Cost‑effectiveness analysis of tislelizumab plus chemotherapy in Chinese patients with advanced or metastatic oesophageal squamous cell carcinoma
Asymptomatic recurrence detection and cost-effectiveness in urothelial carcinoma
Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
Cost-Effectiveness of Fruquintinib for Refractory Metastatic Colorectal Cancer in the USA
Merkel cell carcinoma
Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma
Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma